Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings

Fang Cheng, Qiang Li, Zheng Cui, Hong Mei, Wei‐Ming Li, Yu ZhangFrontiers in Oncology 2023 · DOI

This review paper, published in Frontiers in Oncology, synthesizes the evolving landscape of Chronic Myeloid Leukemia (CML) treatment, moving away from "one-size-fits-all" high-dose therapy toward personalized dose optimization. The authors highlight that for many patients, reducing or even discontinuing Tyrosine Kinase Inhibitors (TKIs) is not only safe but essential for improving quality of life without sacrificing long-term survival.

TL;DR

Tyrosine Kinase Inhibitors (TKIs) have turned CML into a manageable chronic condition, but long-term side effects remain a major hurdle. This review demonstrates that dose reduction and treatment discontinuation (Treatment-Free Remission) are viable, evidence-based strategies to minimize toxicity while maintaining deep molecular control of the disease.

What Problem Does This Paper Address?

Since the introduction of imatinib (Gleevec), the life expectancy of a CML patient in the chronic phase has approached that of the general population. However, this success comes at a cost: patients often face decades of daily medication. Long-term TKI use is associated with significant adverse events (AEs), ranging from chronic fatigue and gastrointestinal issues to severe risks like pleural effusion (fluid around the lungs) and arterial thrombosis.

These side effects lead to poor compliance and reduced quality of life. The central challenge the authors address is: Can we lower the dose or stop the drug entirely without the leukemia returning? The paper explores the transition from clinical trial protocols to "real-life" clinical practice, where patient-specific factors like age and comorbidities demand a more flexible approach.

Methods

As a comprehensive review, this paper does not introduce a new laboratory method but rather performs a meta-synthesis of over 90 studies, including landmark clinical trials (such as STIM1, DASISION, and ENESTnd). The authors categorize the evidence into three main strategies:

  1. Dose Reduction: Lowering the daily intake to manage side effects.
  2. Therapeutic Drug Monitoring (TDM): Using blood plasma levels to personalize dosing.
  3. Treatment-Free Remission (TFR): Stopping the drug entirely in patients who have achieved a stable, "deep molecular response" (DMR).

Datasets

The authors analyze data from several major clinical trial cohorts, including:

  • Imatinib trials: RIGHT, Baccarani et al., and the DESTINY study.
  • Dasatinib trials: DASISION and CA180-034.
  • Nilotinib trials: ENESTnd and ENESTfreedom.
  • Discontinuation benchmarks: Data from the STIM, TWISTER, and EURO-SKI trials, which involve hundreds of patients across Europe and Asia.

Key Insights and Ideas

  • The "Sweet Spot" via TDM: Imatinib concentrations in the blood vary wildly between individuals. The authors argue that Therapeutic Drug Monitoring can identify patients who are "over-dosed," allowing for a reduction that maintains efficacy while slashing side effects.
  • Less is More for Dasatinib: While 100mg is the standard dose for dasatinib, the review highlights that 50mg—or even 20mg in older patients—can maintain a major molecular response (MMR) with a significantly lower risk of pleural effusion.
  • The Tapering Prelude: One of the most interesting insights is from the DESTINY study, which suggests that tapering to a half-dose for 12 months before stopping completely may be a more effective path to TFR than abrupt discontinuation.
  • The Safety Net of Restarting: For patients who attempt to stop therapy and experience a molecular relapse, the "aha moment" is the high success rate of restarting: nearly all patients regain their previous deep molecular response quickly upon resuming the TKI.
  • Second Chances: If a first attempt at TFR fails, a second attempt after regaining a stable DMR is successful in approximately 30–50% of cases.

Key Results

  • TFR Success Rates: Across multiple trials, roughly 40% to 60% of patients with a sustained deep molecular response can successfully stop their medication without the disease returning.
  • AE Reduction: In the TDM-guided groups, cumulative prevalence of side effects like pleural effusion dropped from 39% to 12% over three years when doses were optimized.
  • Molecular Stability: Dose reduction in patients who had already achieved MMR did not lead to disease progression, suggesting that the "maintenance dose" required to keep CML at bay is often much lower than the "induction dose" used to first achieve remission.

Limitations and Future Work

  • Pediatric Gap: Most data comes from adult populations. Children with CML face unique challenges, such as growth disturbances caused by TKIs, and the criteria for safe TFR in pediatrics are still being refined.
  • Predictive Biomarkers: While we know that about half of patients can stop therapy, we still lack perfect biomarkers to predict which specific individuals will relapse.
  • Real-World Monitoring: Transitioning these strategies from controlled trials to general practice requires robust molecular monitoring (PCR testing) every 4–6 weeks, which may not be accessible in all global healthcare settings.

The authors conclude that the future of CML care lies in "individualized therapeutic regimens," where the goal is no longer just survival, but survival with the highest possible quality of life.

Summary updated

Abstract

With the advent of tyrosine kinase inhibitors (TKIs), the treatment prospects of chronic myeloid leukemia (CML) have changed markedly. This innovation can lengthen the long-term survival of patients suffering from CML. However, long-term exposure to TKIs is accompanied by various adverse events (AEs). The latter affect the quality of life and compliance of patients with CML, and may lead to serious disease progression (and even death). Recently, increasing numbers of patients with CML have begun to pursue a dose optimization strategy. Dose optimization may be considered at all stages of the entire treatment, which includes dose reduction and discontinuation of TKIs therapy. In general, reduction of the TKI dose is considered to be an important measure to reduce AEs and improve quality of life on the premise of maintaining molecular responses. Furthermore, discontinuation of TKIs therapy has been demonstrated to be feasible and safe for about half of patients with a stable optimal response and a longer duration of TKI treatment. This review focuses mainly on the latest research of dose optimization of imatinib, dasatinib, and nilotinib in CML clinical trials and real-life settings. We consider dose reduction in newly diagnosed patients, or in optimal response, or for improving AEs, either as a prelude to treatment-free remission (TFR) or as maintenance therapy in those patients unable to discontinue TKIs therapy. In addition, we also focus on discontinuation of TKIs therapy and second attempts to achieve TFR.
BibTeX
@inproceedings{cheng2023dose,
  author = {Fang Cheng and Qiang Li and Zheng Cui and Hong Mei and Wei‐Ming Li and Yu Zhang},
  title = {{Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1146108},
}
Figure